Neurocrine Biosciences Announces Phase 2 Clinical Study for NBI-1065890
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a prominent biopharmaceutical company, has embarked on an exciting new journey with the initiation of its Phase 2 clinical study of the investigational compound NBI-1065890 in adult patients diagnosed with tardive dyskinesia (TD). This innovative treatment is designed to inhibit a protein known as vesicular monoamine transporter 2 (VMAT2) that plays a key role in neuronal signaling. The development of NBI-1065890 is part of Neurocrine's long-standing commitment to addressing complex neurological conditions.
Overview of NBI-1065890
NBI-1065890 represents a significant advancement in the fight against tardive dyskinesia, a movement disorder that causes involuntary muscle movements and is often linked to the use of certain psychiatric medications. The molecule has been developed with distinct properties aimed at potentially providing an improved therapeutic profile for patients who suffer from TD. Dr. Sanjay Keswani, Chief Medical Officer, emphasized the importance of this study in understanding VMAT2's role in neurological health.
Study Design and Goals
The Phase 2 study is designed as a randomized, double-blind, placebo-controlled trial that aims to enroll around 100 adult participants. Its primary objective is to evaluate the efficacy of NBI-1065890, focusing on its impact on the Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score after 8 weeks. By effectively comparing the investigational drug against a placebo, the study aims to generate compelling data that can inform future clinical decisions and potentially provide new hope for many patients struggling with this challenging condition.
Importance of Tardive Dyskinesia
Tardive dyskinesia is characterized by abnormal, uncontrolled movements primarily affecting the face and torso. This condition can have profound consequences for those affected, leading to significant impairment in daily activities and quality of life. It often arises as a side effect of certain antipsychotic medications, which can dysregulate dopamine pathways within the brain. According to estimates, tardive dyskinesia impacts at least 800,000 adults in the United States, emphasizing the necessity of developing effective treatments.
Previous Achievements by Neurocrine
Neurocrine has a robust history in advancing innovative treatments. In 2017, the company successfully gained FDA approval for valbenazine, marking a milestone as the first-ever drug approved specifically for tardive dyskinesia. More recently, in 2023, valbenazine received approval as a treatment for chorea associated with Huntington's disease, further showcasing Neurocrine's commitment to improving patient health outcomes.
Research Commitment
Neurocrine's dedication extends beyond just their current pipeline. The company focuses on creating life-changing treatments for patients with neurological, psychiatric, and endocrine disorders, continuously seeking avenues for research and development. With an impressive portfolio of FDA-approved products and a variety of promising candidates in clinical trials, Neurocrine follows its mission to relieve patient suffering through brave science.
As the Phase 2 clinical study of NBI-1065890 progresses, stakeholders are eager to observe how this innovative approach to VMAT2 inhibition may reshape the future of treatment for tardive dyskinesia. The enthusiasm surrounding this novel therapy speaks to a shared hope for improved therapeutic options in what has long been an underserved area of medical treatment.
Frequently Asked Questions
What is NBI-1065890?
NBI-1065890 is an investigational compound developed by Neurocrine Biosciences aimed at treating tardive dyskinesia through selective inhibition of VMAT2.
What is tardive dyskinesia?
Tardive dyskinesia is a serious movement disorder characterized by involuntary, repetitive movements, often as a side effect of certain antipsychotic medications.
What are the goals of the Phase 2 study?
The Phase 2 study aims to assess the efficacy, safety, and tolerability of NBI-1065890 compared to a placebo over an 8-week period.
How many participants will be involved in the study?
Approximately 100 adult subjects with tardive dyskinesia will be enrolled in the Phase 2 study.
Why is Neurocrine hopeful about NBI-1065890?
The company believes that NBI-1065890 can offer a differentiated treatment profile and could benefit a broader range of patients based on its unique properties.
